## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the abstract; no access to full methods, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors propose MAResNet, a deep-learning architecture combining multi-scale bottom-up and top-down attention mechanisms with a residual network, for predicting transcription factor binding sites. They report an average AUC of 0.927 across 690 ChIP-seq test subsets, claim superiority over current state-of-the-art methods, and assert that attention-aware feature visualization via TMAP demonstrates extraction of unique binding site characteristics.
- **Visible evidence base** Abstract text only; no methodological details, quantitative comparisons, or visualizations are provided in the supplied material
- **Missing materials affecting confidence** Full methods section, architecture diagrams, hyperparameter settings, training/validation protocols, baseline method descriptions, statistical significance tests, all figures and tables, and supplementary data

## Reviewer
- **Overall assessment** The abstract presents a plausible deep-learning framework for transcription factor binding site prediction, with a strong reported performance metric. However, the supplied material is insufficient to evaluate the technical soundness, novelty, or robustness of the claims. The core assertion of state-of-the-art performance cannot be verified without detailed comparisons and statistical analysis. The interpretability claims, while interesting, lack supporting evidence in the abstract.
- **Who would be interested in the results, and why** Computational biologists and bioinformaticians working on regulatory genomics, particularly those developing or applying deep-learning methods for sequence-based functional prediction. Researchers interested in attention mechanisms for biological sequence analysis and model interpretability would also find the approach relevant.
- **Major strengths** The combination of multi-scale bottom-up and top-down attention with residual networks is a conceptually interesting architectural choice. The scale of evaluation (690 ChIP-seq datasets) suggests broad applicability. The explicit focus on model interpretability through attention feature analysis and TMAP visualization addresses an important gap in the field.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
- **Technical failings that need to be addressed before the case is established** R1-M1 (comparison methodology), R1-M2 (statistical rigor), R1-M3 (interpretability evidence)
- **Assessment against Nature-style criteria** 
  - Originality: The architectural combination appears novel, but the abstract does not clearly differentiate it from prior attention-based models for TF binding site prediction. The novelty claim is plausible but not fully established from the supplied material.
  - Scientific importance: Accurate TF binding site prediction is a well-recognized problem with broad relevance to gene regulation and disease research. The potential improvement in performance and interpretability is scientifically valuable.
  - Interdisciplinary readership: The work bridges deep learning and genomics, which has broad appeal. However, the abstract assumes familiarity with both domains, and the presentation may not be fully accessible to nonspecialists in either field.
  - Technical soundness: Cannot be assessed from the abstract alone. The reported AUC of 0.927 is promising, but the lack of methodological detail and statistical validation prevents evaluation of technical rigor.
  - Readability for nonspecialists: The abstract is reasonably clear but uses domain-specific terminology (e.g., "funnel attention modules", "TMAP") without sufficient explanation for a general scientific audience.
- **Recommendation posture** Currently not established from the provided evidence. The abstract presents an interesting approach with a strong reported metric, but the absence of methodological detail, comparative analysis, and statistical validation means the core claims cannot be verified. A full manuscript review would be required to determine whether the technical concerns can be resolved.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Comparative performance claim
- **Claim pointer** "The performance of MAResNet is extensively tested on 690 test subsets with an average AUC of 0.927, which is higher than that of the current state-of-the-art methods."
- **Evidence pointer** Abstract, performance statement; no comparison data provided
- **Concern** The claim of superiority over state-of-the-art methods is made without specifying which methods were compared, the evaluation protocol, or the magnitude of improvement. No baseline results, confidence intervals, or statistical tests are reported.
- **Why it matters** A performance claim of this nature is the central contribution of the work. Without transparent comparison to established methods under identical conditions, the claim cannot be independently verified, and the practical value of MAResNet remains unclear.
- **Resolution test** Provide a table comparing MAResNet against at least 3-5 published methods on the same 690 datasets, including standard deviations or confidence intervals, and report statistical significance tests (e.g., paired t-test or Wilcoxon signed-rank test) for the performance differences.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Statistical robustness
- **Claim pointer** "an average AUC of 0.927" across 690 test subsets
- **Evidence pointer** Abstract, performance statement; no distribution or variance data provided
- **Concern** The average AUC is reported as a single point estimate. No information is provided about the variance across the 690 datasets, the range of AUC values, or whether certain types of transcription factors or chromatin contexts perform poorly. This is critical for assessing the generalizability and reliability of the method.
- **Why it matters** A high average can mask substantial variability. If the method performs poorly on certain TF families or genomic contexts, the practical utility is diminished. The lack of variance reporting prevents assessment of consistency and robustness.
- **Resolution test** Report the distribution of AUC values across the 690 datasets (e.g., boxplot or histogram), identify any outlier or low-performing categories, and discuss potential reasons for variability.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Interpretability claim
- **Claim pointer** "The features learned by MAResNet are also visualized through the TMAP tool to illustrate that the method can extract the unique characteristics of transcription factor binding sites."
- **Evidence pointer** Abstract, interpretability statement; no visualization or analysis provided
- **Concern** The claim that TMAP visualization demonstrates extraction of unique characteristics is unsupported in the abstract. No details are given about what the visualization shows, how uniqueness is defined, or how this relates to biological relevance. The interpretability analysis is presented as a conclusion without supporting evidence.
- **Why it matters** Interpretability is a stated motivation for the work. If the visualization does not clearly demonstrate biologically meaningful feature extraction, the added value of the attention mechanism over standard deep-learning approaches is not established.
- **Resolution test** Include the TMAP visualization with clear annotation of TF binding site clusters, provide quantitative or qualitative evidence that the learned features distinguish binding sites from non-binding regions, and relate the identified features to known sequence motifs or biological properties.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Terminology clarity
- **Affected element** "funnel attention modules"
- **Evidence pointer** Abstract, architecture description
- **Issue** The term "funnel attention modules" is used without definition or explanation. It is unclear whether this is a novel concept or a repurposing of existing attention mechanisms.
- **Required correction** Define the term explicitly in the abstract or use more standard terminology that is immediately understandable to the target audience.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Dataset description
- **Affected element** "690 ChIP-seq datasets"
- **Evidence pointer** Abstract, dataset description
- **Issue** No information is provided about the source of these datasets, the diversity of transcription factors represented, or the species. This limits the reader's ability to assess the scope and potential biases of the evaluation.
- **Required correction** Briefly specify the data source (e.g., ENCODE, Cistrome), the range of transcription factors, and the species covered.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Accessibility of interpretability tool
- **Affected element** "TMAP tool"
- **Evidence pointer** Abstract, interpretability statement
- **Issue** TMAP is referenced without context. Readers unfamiliar with this tool may not understand what it does or why it is appropriate for this analysis.
- **Required correction** Provide a brief description of TMAP and its relevance to visualizing high-dimensional feature spaces in the context of genomic sequences.

## Risk / unsupported claims
- The claim of state-of-the-art performance (average AUC 0.927) is unsupported without detailed baseline comparisons and statistical testing.
- The claim that TMAP visualization demonstrates extraction of unique TF binding site characteristics is unsupported without the actual visualization and analysis.
- The novelty of the architectural combination (multi-scale bottom-up and top-down attention with residual networks) is plausible but not verifiable from the abstract alone.
- The generalizability of the method across diverse transcription factors and genomic contexts is not assessable without variance data and dataset composition details.